DPAg (VEGFR-2 + PD-1 + LTβR agonist) therapy for 10–13 days (PyMT) or 8 days (E0771) and stopped the treatment and followed tumour growth for 2 weeks. This evidence concerns the gene LTBR and neoplasm.